IQ EQ FUND MANAGEMENT IRELAND Ltd Invests $402,000 in Twist Bioscience Co. (NASDAQ:TWST)

IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Twist Bioscience Co. (NASDAQ:TWST) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 8,153 shares of the company’s stock, valued at approximately $402,000.

Other hedge funds also recently modified their holdings of the company. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the 4th quarter valued at $30,000. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the period. Nisa Investment Advisors LLC raised its holdings in Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares during the period. CWM LLC raised its holdings in Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after acquiring an additional 524 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Twist Bioscience during the 1st quarter valued at $124,000.

Twist Bioscience Stock Down 4.7 %

Shares of NASDAQ:TWST traded down $2.09 during midday trading on Friday, hitting $42.81. 499,723 shares of the stock traded hands, compared to its average volume of 1,013,552. The stock has a market capitalization of $2.49 billion, a PE ratio of -12.67 and a beta of 1.80. The business’s 50 day moving average is $49.17 and its two-hundred day moving average is $42.59. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same period last year, the company posted ($1.01) earnings per share. The business’s revenue was up 27.7% on a year-over-year basis. As a group, sell-side analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares of the company’s stock, valued at $3,154,310.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Twist Bioscience news, COO Patrick John Finn sold 2,885 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $115,198.05. Following the transaction, the chief operating officer now directly owns 168,327 shares in the company, valued at $6,721,297.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dennis Cho sold 709 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the transaction, the insider now owns 78,996 shares in the company, valued at $3,154,310.28. The disclosure for this sale can be found here. Insiders sold a total of 21,327 shares of company stock valued at $978,760 over the last three months. Corporate insiders own 3.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Barclays reduced their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Evercore ISI boosted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. The Goldman Sachs Group boosted their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. TD Cowen upped their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.